Complement C5 inhibitor: revolutionizing treatment for refractory anti-acetylcholine receptor antibody positive generalized myasthenia gravis
Journal of Neurocritical Care · 26.06.2026 · 19 (1) · 53-57
DOI: 10.18700/jnc.250040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurocritical Care, online erschienen am 26.06.2026. Verfasst von Kit Mun Loke und 1 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Recently, increasing evidence has demonstrated the rapid beneficial effect of monoclonal antibodies blocking the terminal complement protein C5 in refractory generalized myasthenia gravis (gMG); therefore, they have emerged as a promising option for fast-acting therapy (FT). Case Report: We describe the case of a 21-year-old female with a 4-year history of non-thymomatous anti-acetylcholine receptor antibody (anti-AChR Ab) positive refractory gMG (Myasthenia Gravis Foundation of America [MGFA] class V) who responded to complement C5 inhibitor within the first week, achieving minimal symptom expression within 2 months. This rapid-onset efficacy challenged the existing understanding of antibody-mediated destruction of AChR, where instant restoration of neuromuscular junction neurotransmission from recovery of the destroyed postsynaptic membrane of the motor endplate and reduction in the number of AChR receptors is theoretically not possible with membrane attack complex inhibition.
Conclusion
The rapid target attainment effect of complement inhibition can be considered as an additional novel indication for conventional FT.
Zitieren
APA
Loke, K. M., & Hiew, F. L. (2026). Complement C5 inhibitor: revolutionizing treatment for refractory anti-acetylcholine receptor antibody positive generalized myasthenia gravis. Journal of Neurocritical Care, 19(1), 53-57. https://doi.org/10.18700/jnc.250040
Vancouver
Loke KM, Hiew FL. Complement C5 inhibitor: revolutionizing treatment for refractory anti-acetylcholine receptor antibody positive generalized myasthenia gravis. Journal of Neurocritical Care. 2026;19(1):53-57. doi:10.18700/jnc.250040
BibTeX
@article{Loke2026,
author = {Loke, Kit Mun and Hiew, Fu Liong},
title = {Complement C5 inhibitor: revolutionizing treatment for refractory anti-acetylcholine receptor antibody positive generalized myasthenia gravis},
journal = {Journal of Neurocritical Care},
year = {2026},
volume = {19},
number = {1},
pages = {53--57},
doi = {10.18700/jnc.250040}
}
EUVIMED